348 related articles for article (PubMed ID: 31364001)
1. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
Zhou H; Wang XJ; Jiang X; Qian Z; Chen T; Hu Y; Chen ZH; Gao Y; Wang R; Ye WW; Cao WM
Breast Cancer Res Treat; 2019 Nov; 178(1):63-73. PubMed ID: 31364001
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer.
Mo H; Wang X; Ma F; Qian Z; Sun X; Yi Z; Guan X; Li L; Liu B; Xu B
Breast; 2020 Oct; 53():111-118. PubMed ID: 32738630
[TBL] [Abstract][Full Text] [Related]
3. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of plasma cfDNA concentration and integrity in breast cancer patients.
Miao Y; Fan Y; Zhang L; Ma T; Li R
Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):64-72. PubMed ID: 31472049
[TBL] [Abstract][Full Text] [Related]
5. Cell-Free DNA Variables including Gene Mutations in CA15-3 Normal Breast Cancer Reflect Prognosis.
Xu J; Chen W; Sun Z; Peng H; Zhou C; Pan S
Dis Markers; 2022; 2022():5470166. PubMed ID: 35251373
[TBL] [Abstract][Full Text] [Related]
6. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
7. High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer.
Zhu L; Pan JN; Qian Z; Ye WW; Wang XJ; Cao WM
Breast Cancer; 2022 Jan; 29(1):103-113. PubMed ID: 34403063
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
[TBL] [Abstract][Full Text] [Related]
9. FTO, PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer.
Mi J; Zhang H; Cao W; Yuan C
Medicine (Baltimore); 2023 Oct; 102(42):e35361. PubMed ID: 37861518
[TBL] [Abstract][Full Text] [Related]
10. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
Park BJ; Cha MK; Kim IH
BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer.
Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H
Breast Cancer; 2003; 10(3):220-7. PubMed ID: 12955034
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
13. CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer.
Svobodova S; Kucera R; Fiala O; Karlikova M; Narsanska A; Zedníková I; Treska V; Slouka D; Rousarova M; Topolcan O; Finek J
Anticancer Res; 2018 Jan; 38(1):465-469. PubMed ID: 29277810
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
Yang X; Zhang K; Zhang C; Peng R; Sun C
BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
[TBL] [Abstract][Full Text] [Related]
15. A Case-Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection.
Bortul M; Giudici F; Tierno D; Generali D; Scomersi S; Grassi G; Bottin C; Cappelletti MR; Zanconati F; Scaggiante B
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239866
[TBL] [Abstract][Full Text] [Related]
16. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
Zhang SJ; Hu Y; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
Asian Pac J Cancer Prev; 2013; 14(6):3937-40. PubMed ID: 23886210
[TBL] [Abstract][Full Text] [Related]
17. Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer.
Fernandez-Garcia D; Hills A; Page K; Hastings RK; Toghill B; Goddard KS; Ion C; Ogle O; Boydell AR; Gleason K; Rutherford M; Lim A; Guttery DS; Coombes RC; Shaw JA
Breast Cancer Res; 2019 Dec; 21(1):149. PubMed ID: 31856868
[TBL] [Abstract][Full Text] [Related]
18. Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing.
Ge G; Peng D; Guan B; Zhou Y; Gong Y; Shi Y; Hao X; Xu Z; Qi J; Lu H; Zhang X; Zhan Y; Li Y; Wu Y; Ding G; Shen Q; He Q; Li X; Zhou L; Ci W
Clin Chem; 2020 Jan; 66(1):188-198. PubMed ID: 31811000
[TBL] [Abstract][Full Text] [Related]
19. CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause.
Wang XF; Wu YH; Wang MS; Wang YS
Asian Pac J Cancer Prev; 2014; 15(1):363-8. PubMed ID: 24528057
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide cell-free DNA methylation analyses improve accuracy of non-invasive diagnostic imaging for early-stage breast cancer.
Liu J; Zhao H; Huang Y; Xu S; Zhou Y; Zhang W; Li J; Ming Y; Wang X; Zhao S; Li K; Dong X; Ma Y; Qian T; Chen X; Xing Z; Zhang Y; Chen H; Liu Z; Pang D; Zhou M; Wu Z; Wang X; Wang X; Wu N; Su J
Mol Cancer; 2021 Feb; 20(1):36. PubMed ID: 33608029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
